drugset / Trial / NCT04475991
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Phase 2
Terminated
19 enrolled
Hospital General de México Dr. Eduardo Liceaga
CCINSHAE. Secretaría de Salud. México · collabCentro de Investigación en. Enfermedades Infecciosas, Mexico · collabInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase 2, randomized, open-label study to evaluate the safety and efficacy of maraviroc, favipiravir, and both drugs administered along with currently used therapy in hospitalized patients with pulmonary SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection (COVID-19)
Timeline
- Start
- 2021-07-13
- Primary completion
- 2022-03-15
- Completion
- 2022-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 600 mg | Oral |
| Subject | Maraviroc | Other / unclassified | 300 mg | Oral |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Enoxaparin sodium | Other / unclassified | — | — |